In the literature, there is also the classic example of statins, which are drugs that act to reduce dyslipidemia and have competitive kinetics, competing reversibly with 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) for an active site of the enzyme HMG-CoA reductase, inhibiting the synthesis of cholesterol [71]. This evidence concerns the gene HMGCR and metabolic syndrome.